Your browser doesn't support javascript.
loading
Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.
Bustoros, Mark; Sklavenitis-Pistofidis, Romanos; Park, Jihye; Redd, Robert; Zhitomirsky, Benny; Dunford, Andrew J; Salem, Karma; Tai, Yu-Tzu; Anand, Shankara; Mouhieddine, Tarek H; Chavda, Selina J; Boehner, Cody; Elagina, Liudmila; Neuse, Carl Jannes; Cha, Justin; Rahmat, Mahshid; Taylor-Weiner, Amaro; Van Allen, Eliezer; Kumar, Shaji; Kastritis, Efstathis; Leshchiner, Ignaty; Morgan, Elizabeth A; Laubach, Jacob; Casneuf, Tineke; Richardson, Paul; Munshi, Nikhil C; Anderson, Kenneth C; Trippa, Lorenzo; Aguet, François; Stewart, Chip; Dimopoulos, Meletios-Athanasios; Yong, Kwee; Bergsagel, P Leif; Manier, Salomon; Getz, Gad; Ghobrial, Irene M.
Afiliación
  • Bustoros M; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Sklavenitis-Pistofidis R; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.
  • Park J; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Redd R; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Zhitomirsky B; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.
  • Dunford AJ; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Salem K; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Tai YT; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Anand S; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA.
  • Mouhieddine TH; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Chavda SJ; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Boehner C; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Elagina L; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Neuse CJ; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Cha J; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Rahmat M; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.
  • Taylor-Weiner A; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Van Allen E; Department of Hematology, University College London, London, United Kingdom.
  • Kumar S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Kastritis E; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.
  • Leshchiner I; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Morgan EA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Laubach J; Faculty of Medicine, University of Münster, Münster, Germany.
  • Casneuf T; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Richardson P; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Munshi NC; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.
  • Anderson KC; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Trippa L; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Aguet F; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Stewart C; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Dimopoulos MA; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Yong K; Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
  • Bergsagel PL; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Manier S; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Getz G; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Ghobrial IM; Janssen Research and Development, Beerse, Belgium.
J Clin Oncol ; 38(21): 2380-2389, 2020 07 20.
Article en En | MEDLINE | ID: mdl-32442065
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Genómica / Secuenciación de Nucleótidos de Alto Rendimiento / Mieloma Múltiple Quiescente Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Oncol Año: 2020 Tipo del documento: Article País de afiliación: Marruecos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Genómica / Secuenciación de Nucleótidos de Alto Rendimiento / Mieloma Múltiple Quiescente Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Oncol Año: 2020 Tipo del documento: Article País de afiliación: Marruecos Pais de publicación: Estados Unidos